The Johns Hopkins University Applied Physics Laboratory (APL), with help from The Boeing Company [NYSE: BA] and Iridium Communications Inc. [Nasdaq: IRDM], has successfully implemented a new space-based system to monitor Earth’s space environment. Known as the Active Magnetosphere and Planetary Electrodynamics Response Experiment (AMPERE), the system provides real-time magnetic field measurements using commercial satellites as part of a new observation network to forecast weather in space. This is the first step in developing a system that enables 24-hour tracking of Earth's response to supersonic blasts of plasma ejected from the sun at collection rates fast enough to one day enable forecasters to predict space weather effects.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/iridium/45153/
Every dog has his day. And yesterday, Atlanta-area dogs sure had theirs, as its first Dream Dog Park was unveiled by Beneful® brand dog food in Johns Creek, Ga.
The entire Johns Creek dog-loving community has awaited this day since last September, when their community dog park was awarded a $500,000 renovation from the Beneful® brand after local resident Pat McNeely and his Siberian Husky Koda were named Grand Prize Winner in the Beneful® WagWorld® Dream Dog Park Contest. Since then, Pat and Koda’s dream ideas have served as inspiration for the renovation that was managed by the Beneful Dream Team, led by TV personality and design expert Jason Cameron and pet expert and bestselling author Arden Moore. The Dream Team duo have worked together to transform the Newtown Dog Park into an enviable adventure destination for dogs and owners. Some of the park’s most interactive and unique elements include a giant bone-shaped ramp with tunnels, two water splash pads and a running trail, all of which were put to good use yesterday as local dogs and their best buddies turned out to celebrate at a special unveiling event.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/benefuldreamdogpark/50201/
The following statement is being issued by Jonathan Schochor, Chairman, Plaintiffs’ Steering Committee, regarding Jane Doe No. 1, et. al. v. Johns Hopkins Hospital, et al., No. 24-C-13-001041.
If you were a patient of, or treated by Johns Hopkins Hospital gynecologist, Dr. Nikita Levy, you are a member of a mandatory settlement class action.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65136-dr-nikita-levy-class-action-lawsuit-johns-hopkins-hospital-gynecology
The following statement is being issued by Jonathan Schochor, Chairman, Plaintiffs’ Steering Committee, regarding Jane Doe No. 1, et. al. v. Johns Hopkins Hospital, et al., No. 24-C-13-001041.
If you were a patient of, or were treated by Johns Hopkins Hospital gynecologist, Dr. Nikita Levy, you may be eligible for compensation from a class action Settlement
A $190 million dollar proposed Settlement has been reached that offers payments to eligible members of The Levy Settlement Class.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7281851-dr-nikita-levy-patients-class-action-settlement/
Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
